Please assess the completion status of the following clinical trial:

Trial Title: Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-44 years~* Must be biologically female (defined as sex at birth)~* HIV negative women with at least one of the following risk factors in the past 5 years~  1. Injection drug use or use of crack, cocaine, heroin, or methamphetamine~ 2. Diagnosed with a sexually transmitted infection~ 3. Unprotected sex with 3 or more men~ 4. Having sex for drugs, money, or shelter~ 5. Sex with a known HIV-positive man~ 6. Having a partner meeting any of the preceding criteria~* Normal menses (within 22-35 day intervals) for at least 3 cycles~* No history of alcohol abuse, heart disease, or liver disease, or any other medical condition that would interfere with the conduct of the study, in the opinion of the study investigator~* No history of loop electrosurgical excision procedure (LEEP), conization, or cryosurgery~* Normal chemistry, liver function, and complete blood count panels at screening, including:~  1. Absolute neutrophil count (ANC) ≥ 750/mm3~ 2. Hemoglobin ≥ 10.0 g/dL~ 3. Platelet count ≥ 100,000/mm3~ 4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 3 x Upper Limit Normal (ULN)~ 5. Total bilirubin ≤ 2.5 x ULN~ 6. Creatinine Clearance (CrCl) ≥ 60 mL/min as estimated by the Cockcroft-Gault equation~* Negative hepatitis B surface antigen (HBsAg)~* No signs or symptoms of orthostasis~* No signs or symptoms of vaginal infection or genital ulcer disease at screening or untreated vaginal infection in the last 30 days~* Not receiving concurrent medications that interact with maraviroc (MVC) or any antiretrovirals (such as tenofovir/ emtricitabine \[Truvada®\]) for the purpose of HIV prevention~* Willing to use condoms for the duration of the study and abstain from sexual intercourse for 48 hours before each genital tract sampling~Exclusion Criteria:~* Male sex (defined as sex at birth)~* Pregnant or breastfeeding~* Current use of systemic hormonal contraception~* Symptomatic vaginal infection or genital ulcer disease at screening or treatment for vaginal infection in the last two weeks~* Active malignancy for which the participant is undergoing evaluation and/or treatment~* Immunosuppressive medications (i.e, systemic steroids)~* Any surgery in the preceding 2 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Truvada qd (Type: EXPERIMENTAL): Women will be assigned at random Truvada 1 tablet PO daily
- Maraviroc 300 qd (Type: EXPERIMENTAL): Women will be assigned at random Maraviroc 300 mg PO daily

Based on this trial design, predict the completion outcome and termination type (if applicable).